Inal A, Altintas D U, Yilmaz M, Karakoc G B, Kendirli S G, Sertdemir Y
Division of Pediatric Allergy and Immunology, Faculty of Medicine, Cukurova University, Adana, Turkey.
J Investig Allergol Clin Immunol. 2007;17(2):85-91.
Previous studies have suggested that single-allergen-specific immunotherapy (SIT) may prevent sensitization to other airborne allergens in monosensitized children. We aimed to assess the prevention of new sensitizations in monosensitized children treated with single-allergen SIT injections in comparison with monosensitized patients given appropriate pharmacologic treatment for their disease.
A total of 147 children with rhinitis and/or asthma monosensitized to house dust mite were studied; 45 patients underwent SIT with adsorbed extracts and 40 patients underwent SIT with aqueous extracts for 5 years. The control group was comprised of 62 patients given only pharmacologic treatment for at least 5 years. Skin prick tests, medication scores for rhinitis and asthma, and atopy scores according to skin prick tests were evaluated at the beginning and after 5 years of treatment.
All groups were comparable in terms of age, sex, and disease characteristics. At the end of 5 years, 64 out of 85 (75.3%) in the SIT group showed no new sensitization, compared to 29 out of 62 children (46.7%) in the control group (P = .002). There were no differences between the SIT subgroups with regard to onset of new sensitization (P = .605). The patients developing new sensitizations had higher atopy scores (P = .002) and medication scores for both rhinitis (P = .008) and asthma (P = .013) in comparison to patients not developing new sensitizations after 5 years of SIT.
According to our data, SIT has the potential to prevent the onset of new sensitizations in children with rhinitis and/or asthma monosensitized to house dust mite.
先前的研究表明，单过敏原特异性免疫疗法（SIT）可能会预防单敏儿童对其他空气传播过敏原的致敏。我们旨在评估接受单过敏原SIT注射治疗的单敏儿童与接受针对其疾病的适当药物治疗的单敏患者相比，预防新致敏的情况。
共研究了147名单敏于屋尘螨的鼻炎和/或哮喘儿童；45例患者接受吸附提取物的SIT治疗，40例患者接受水提取物的SIT治疗，为期5年。对照组由62例仅接受药物治疗至少5年的患者组成。在治疗开始时和5年后评估皮肤点刺试验、鼻炎和哮喘的药物评分以及根据皮肤点刺试验得出的特应性评分。
所有组在年龄、性别和疾病特征方面具有可比性。5年后，SIT组85例中有64例（75.3%）未出现新的致敏，而对照组62例儿童中有29例（46.7%）未出现新的致敏（P = 0.002）。SIT亚组之间在新致敏的发生方面没有差异（P = 0.605）。与接受SIT治疗5年后未出现新致敏的患者相比，出现新致敏的患者具有更高的特应性评分（P = 0.002）以及鼻炎（P = 0.008）和哮喘（P = 0.013）的药物评分。
根据我们的数据，SIT有可能预防单敏于屋尘螨的鼻炎和/或哮喘儿童出现新的致敏。
